On this episode of Invested, Michael hosts Mati Gill, CEO of AION Labs, Israel’s first global biotech venture studio. Backed by Pfizer, Merck KGaA, AstraZeneca, Teva, and AWS, AION Labs pioneers a new model for company creation: uniting pharma giants, tech leaders, and investors to collaboratively build AI-first startups in drug discovery and development. Instead of the typical biotech trajectory—where most startups fail—AION ensures founders start with the right problem, data, talent, guidance, and backing from day one. Mati brings a rare blend of experiences across pharma, government, and security. Before AION, he was a senior executive at Teva Pharmaceuticals, leading global public policy and advising the CEO during major restructuring. Earlier, he served as Chief of Staff at Israel’s Ministry of Public Security, and as an IDF reserve officer he coordinated international operations with UN peacekeepers.

Please rate this episode 5 stars wherever you stream your podcasts!

KEY TOPICS